Eli Lilly’s weight-loss drug cut the risk of developing type 2 diabetes by 94% in prediabetic adults who were overweight or obese after three years of weekly injections, the company disclosed in a statement on Tuesday. NBC News Health
Eli Lilly’s weight-loss drug cut the risk of developing type 2 diabetes by 94% in prediabetic adults who were overweight or obese after three years of weekly injections, the company disclosed in a statement on Tuesday.